<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803660</url>
  </required_header>
  <id_info>
    <org_study_id>NIS-CVN-DUM-2008/1</org_study_id>
    <nct_id>NCT00803660</nct_id>
  </id_info>
  <brief_title>Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes</brief_title>
  <official_title>In Practice Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-centre survey of type 2 diabetic patients who are currently on anti-hypertensive
      treatment. Data collection for each patient will take place at one visit. To observe the
      proportion of diabetic patients on antihypertensive treatment reaching the BP&lt;130/80 mmHg. To
      observe the proportion of diabetic patients on antihypertensive treatment reaching the
      BP&lt;130/80 mmHg by treatment groups. To observe the proportion of patients achieving a
      therapeutic glycemic response defined as HbA1c=&lt;7%. To observe the proportion of patients
      achieving fasting plasma glucose&lt;110 mg%. To identify factors for not achieving BP&lt;130/80
      mmHg. To describe percentage of patients with positive proteinuria (including
      microalbuminuria) by treatment groups .
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of patients achieving the BP&lt;130/80 mmHg</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>The percentage of patients achieving the BP&lt;130/80 mmHg</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number and percentage of patients achieving the BP&lt;130/80 mmHg by treatment groups</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number and percentage of patients achieving HbA1c=&lt;7%</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number and percentage of patients achieving the FPG&lt;110 mg%</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The association between unachievement of BP&lt;130/80 mmHg and other factors (age, gender, CV risk factors, CV and diabetes history, duration of type of treatment...)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number and percentage of patients with positive proteinuria by treatment groups</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">1060</enrollment>
  <condition>Hypertension</condition>
  <condition>Type 2 Diabetes</condition>
  <eligibility>
    <study_pop>
      <textblock>
        type 2 diabetic patients who are currently using antihypertensive treatment for at least 3
        months, with same regimen for a minimum of 4 weeks prior to the survey
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of written informed consent

          -  Patient was diagnosed with type 2 diabetes

          -  Patient is on antihypertensive treatments for at least 3 months, with the same regimen
             for a minimum of 4 weeks prior to survey

        Exclusion Criteria:

          -  Patients are critically ill, had mental health problems or difficulty in communication

          -  Patients who are unwilling or unable to provide informed consent

          -  Involvement in the planning and conduct of the study (applies to both AstraZeneca
             staff or staff at the study site).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dang Van Phuoc, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Medicine and Pharmacy of HCMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pham Nguyen Vinh, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tam Duc Heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pham Gia Khai, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vietnam Heart Association</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nguyen Thy Khue, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology and Diabetes Association of HCMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Qui Nhon</city>
        <state>Binh Dinh</state>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buon Me Thuoc</city>
        <state>Dak Lak</state>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bien Hoa</city>
        <state>Dong Nai</state>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thong Nhat</city>
        <state>Dong Nai</state>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nha Trang</city>
        <state>Khanh Hoa</state>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hue</city>
        <state>Thua Thien</state>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>An Giang</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bac Lieu</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ca Mau</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Can Tho</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Da Nang</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dong Thap</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hai Phong</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hanoi</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ho Chi Minh</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kien Giang</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nam Dinh</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Thai Binh</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tien Giang</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <last_update_submitted>July 8, 2009</last_update_submitted>
  <last_update_submitted_qc>July 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Vo Viet Tuan</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>hypertension</keyword>
  <keyword>BP</keyword>
  <keyword>diabetes</keyword>
  <keyword>anti-hypertensive treatment</keyword>
  <keyword>ACE-I</keyword>
  <keyword>ARB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

